Aboushousha T, Hammam O, Aref A, Kamel A, Badawy M, Abdel Hamid A. Tissue Profile of CDK4 and STAT3 as Possible Innovative Therapeutic Targets in Urinary Bladder Cancer. Asian Pac J Cancer Prev. 2020;21:547-554 pubmed publisher

Sharma P, Alsharif S, Bursch K, Parvathaneni S, Anastasakis D, Chahine J, et al. Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors. Sci Rep. 2019;9:14650 pubmed publisher

Sriraman A, Dickmanns A, Najafova Z, Johnsen S, Dobbelstein M. CDK4 inhibition diminishes p53 activation by MDM2 antagonists. Cell Death Dis. 2018;9:918 pubmed publisher

Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira N, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91-95 pubmed publisher

Peurala E, Koivunen P, Haapasaari K, Bloigu R, Jukkola Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res. 2013;15:R5 pubmed publisher

Rodier G, Makris C, Coulombe P, Scime A, Nakayama K, Nakayama K, et al. p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2. J Cell Biol. 2005;168:55-66 pubmed